News
Following FDA win, Portola loses CEO William Lis | Raging Topics
business.ragingtopics.com
William Lis. Just one month after Portola won a long-awaited FDA approval of its bleeding antidote for blood thinners, the company's chief ...
Cinque star del biotech Usa - MilanoFinanza.it
www.milanofinanza.it
L’indice Nasdaq Biotechnology, smentendo chi si aspettava l’imminente scoppio di una bolla speculativa, ha realizzato da inizio una performance del...
Casual Andexxa disclosure hints at more Portola delays | Evaluate
www.evaluate.com
Portola often appears near the top of investors’ lists of likely biotech takeover targets, but based on its recent actions you might be excused for thinking...
Portola license Japanese commercial rights for andexanet alfa to...
cardiacrhythmnews.com
... and the third largest market for Factor Xa inhibitors after the USA and EU five countries,” says William Lis, chief executive officer of Portola.
sorted by relevance / date